FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief Financial Officer of Zosano will present at the 7th annual BIO Investor Forum. Mr. Vuko will provide an update on the company’s progress. He will highlight the key features of its proprietary transdermal delivery technology as well as the recent Phase 2 results of its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, being developed as an alternative to daily injections.
